MX2018003663A - Metodo de tratamiento de tumor rabdoide maligno del ovario (mrto) /cancer microcitico del ovario del tipo hipercalcemico (sccoht) con un inhibidor de ezh2. - Google Patents

Metodo de tratamiento de tumor rabdoide maligno del ovario (mrto) /cancer microcitico del ovario del tipo hipercalcemico (sccoht) con un inhibidor de ezh2.

Info

Publication number
MX2018003663A
MX2018003663A MX2018003663A MX2018003663A MX2018003663A MX 2018003663 A MX2018003663 A MX 2018003663A MX 2018003663 A MX2018003663 A MX 2018003663A MX 2018003663 A MX2018003663 A MX 2018003663A MX 2018003663 A MX2018003663 A MX 2018003663A
Authority
MX
Mexico
Prior art keywords
ovary
sccoht
rhabdoid tumor
small cell
cell cancer
Prior art date
Application number
MX2018003663A
Other languages
English (en)
Inventor
Keilhack Heike
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of MX2018003663A publication Critical patent/MX2018003663A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)

Abstract

La divulgación proporciona un método de tratamiento de un tumor rabdoide maligno en un sujeto que lo necesita, que incluye administrar al sujeto una cantidad terapéuticamente eficaz de un potenciador de un inhibidor del homologo zeste 2 (EZH2). En determinadas realizaciones de este método, el tumor rabdoide maligno es cáncer microcítico del ovario del tipo hipercalcémico (SCCOHT) y el inhibidor de EZH2 es tazemetostat (también conocido como Tazemetostat).
MX2018003663A 2015-09-25 2016-09-26 Metodo de tratamiento de tumor rabdoide maligno del ovario (mrto) /cancer microcitico del ovario del tipo hipercalcemico (sccoht) con un inhibidor de ezh2. MX2018003663A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562233146P 2015-09-25 2015-09-25
US201562252188P 2015-11-06 2015-11-06
PCT/US2016/053673 WO2017053930A2 (en) 2015-09-25 2016-09-26 Method of treating malignant rhabdoid tumor of the ovary (mrto)/small cell cancer of the ovary of the hypercalcemic type (sccoht) with an ezh2 inhibitor

Publications (1)

Publication Number Publication Date
MX2018003663A true MX2018003663A (es) 2018-08-14

Family

ID=58387531

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018003663A MX2018003663A (es) 2015-09-25 2016-09-26 Metodo de tratamiento de tumor rabdoide maligno del ovario (mrto) /cancer microcitico del ovario del tipo hipercalcemico (sccoht) con un inhibidor de ezh2.
MX2022013390A MX2022013390A (es) 2015-09-25 2018-03-23 Metodo de tratamiento de tumor rabdoide maligno del ovario (mrto)/cancer microcitico del ovario del tipo hipercalcemico (sccoht) con un inhibidor de ezh2.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022013390A MX2022013390A (es) 2015-09-25 2018-03-23 Metodo de tratamiento de tumor rabdoide maligno del ovario (mrto)/cancer microcitico del ovario del tipo hipercalcemico (sccoht) con un inhibidor de ezh2.

Country Status (12)

Country Link
US (3) US20180296563A1 (es)
EP (1) EP3352761A4 (es)
JP (1) JP7013369B2 (es)
KR (1) KR20180054793A (es)
CN (2) CN114533880B (es)
AU (2) AU2016325643B2 (es)
CA (1) CA2999898A1 (es)
EA (1) EA201890801A1 (es)
IL (2) IL258302A (es)
MX (2) MX2018003663A (es)
SG (1) SG10201908323TA (es)
WO (1) WO2017053930A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2996412A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
JP7013369B2 (ja) * 2015-09-25 2022-02-15 エピザイム，インコーポレイティド Ｅｚｈ２阻害剤により卵巣の悪性ラブドイド腫瘍（ｍｒｔｏ）／高カルシウム血症型の卵巣の小細胞癌（ｓｃｃｏｈｔ）を処置するための方法
JP2019503391A (ja) 2016-01-29 2019-02-07 エピザイム，インコーポレイティド 癌を処置するための併用療法
US11786533B2 (en) 2016-06-01 2023-10-17 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
CN109312407A (zh) * 2016-06-08 2019-02-05 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
EP3471830A4 (en) 2016-06-17 2020-02-26 Epizyme Inc EZH2 INHIBITORS TO TREAT CANCER
EP3576729A4 (en) * 2017-02-02 2021-04-14 Epizyme, Inc. CANCER TREATMENT MODALITIES
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
US11602529B2 (en) 2017-06-02 2023-03-14 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
US11452727B2 (en) 2017-09-05 2022-09-27 Epizyme, Inc. Combination therapy for treating cancer
AU2020248422A1 (en) * 2019-03-26 2021-11-11 Translational Drug Development, Llc Method of treating malignant rhabdoid tumor of the ovary and small cell cancer of the ovary of the hypercalcemic type
CN110950834A (zh) * 2019-11-26 2020-04-03 济南大学 新型eed-ezh2相互作用小分子抑制剂的确定和评价
CN110960525A (zh) * 2019-11-26 2020-04-07 济南大学 新型eed-ezh2相互作用抑制剂的确定和评价

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE028977T2 (en) * 2010-09-10 2017-02-28 Epizyme Inc A method for determining the suitability of human EZH2 inhibitors during treatment
ES2655642T3 (es) * 2011-05-16 2018-02-21 Ulrike Nuber Terapias contra el cáncer novedosas y métodos
CN104540500B (zh) * 2012-03-12 2019-02-22 Epizyme股份有限公司 人ezh2抑制剂及其应用方法
RU2699546C2 (ru) * 2012-04-13 2019-09-06 Эпизайм, Инк. Комбинированная терапия для лечения рака
CA2887243C (en) * 2012-10-15 2024-04-09 Epizyme, Inc. Methods of treating cancer
US20140120083A1 (en) * 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2015103431A1 (en) * 2013-12-31 2015-07-09 Memorial Sloan-Kettering Cancer Center Compositions and methods for the diagnosis and treatment of ovarian cancers that are associated with reduced smarca4 gene expression or protein function
US9775844B2 (en) * 2014-03-19 2017-10-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2996412A1 (en) * 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
JP7013369B2 (ja) * 2015-09-25 2022-02-15 エピザイム，インコーポレイティド Ｅｚｈ２阻害剤により卵巣の悪性ラブドイド腫瘍（ｍｒｔｏ）／高カルシウム血症型の卵巣の小細胞癌（ｓｃｃｏｈｔ）を処置するための方法

Also Published As

Publication number Publication date
AU2016325643A1 (en) 2018-04-12
CA2999898A1 (en) 2017-03-30
MX2022013390A (es) 2023-01-04
CN114533880A (zh) 2022-05-27
US20210121470A1 (en) 2021-04-29
IL258302A (en) 2018-05-31
JP2018529698A (ja) 2018-10-11
CN114533880B (zh) 2023-08-22
SG10201908323TA (en) 2019-10-30
EP3352761A2 (en) 2018-08-01
AU2016325643B2 (en) 2022-07-21
CN108349958B (zh) 2022-02-15
JP7013369B2 (ja) 2022-02-15
IL280760A (en) 2021-04-29
US20200138825A1 (en) 2020-05-07
AU2022256115A1 (en) 2022-11-17
US20180296563A1 (en) 2018-10-18
EP3352761A4 (en) 2019-04-24
KR20180054793A (ko) 2018-05-24
EA201890801A1 (ru) 2018-09-28
CN108349958A (zh) 2018-07-31
WO2017053930A3 (en) 2018-04-12
WO2017053930A2 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
MX2022013390A (es) Metodo de tratamiento de tumor rabdoide maligno del ovario (mrto)/cancer microcitico del ovario del tipo hipercalcemico (sccoht) con un inhibidor de ezh2.
MX2021004881A (es) Combinacion de palbociclib y rad1901 para usarse en el tratamiento de cancer de mama en un sujeto con cancer positivo a receptor de estrogeno.
MX2022001123A (es) Inhibidor de pd-1 para usarse en el tratamiento de cancer de piel.
WO2017176628A8 (en) Methods for solid tumor treatment
MX2017004691A (es) Bloqueo de cd73.
PH12015502855A1 (en) Peptides and petidomimetics in combination uses and treatments for cancer patient subpopulations
CA2919397C (en) Aryl ethers as hif-2.alpha. inhibitors for the treatment of cancer
MY197198A (en) Pharmaceutical composition for preventing or treating breast cancer including crystalline polymorph of tetraarsenic hexoxide, and method for producing same
MX2018004132A (es) Método de tratamiento de meduloblastoma con un inhibidor de ezh2.
EA201991214A1 (ru) Антитела против pd-1 и их композиции
EA201691748A1 (ru) Антитела анти-cd38 для лечения острого лимфобластного лейкоза
NZ730365A (en) Method for treating cancer
WO2017100362A3 (en) Inhibitors of ezh2 and methods of use thereof
MX2023011187A (es) Metodos para tratar el cancer de prostata.
MY201580A (en) Use of ezh2 inhibitor combined with btk inhibitor in preparing drug for treating tumor
BR112019024719A2 (pt) Composições e métodos para resposta imunológica antitumor aprimorada
MX2019004940A (es) Uso de beta-catenina como un biomarcador para el tratamiento de canceres que usan el anticuerpo anti-dkk-1.
MX2019002618A (es) Aptameros especificos para pd 1.
PH12016000355B1 (en) Use of xanthophylls for the treatment of cancers
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
WO2016106357A8 (en) Combination of raf inhibitors and aurora kinase inhibitors
MX2018006776A (es) Usos de pirimido-piridazinonas para tratar el cancer.
MX2020005454A (es) Tratamiento de cancer mejorado.
EA201892813A1 (ru) Иммунотерапия рака
IL286656A (en) A method for the treatment of malignant rhabdoid tumor of the ovary and small cell cancer of the ovary of the hypercalcemic type